The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Researchers found that macrophages are associated with response to chemotherapy before treatment in triple-negative breast cancer.

Sanam Loghavi, MD, discusses the specific updates to the WHO diagnostic criteria in acute myeloid leukemia.

The FDA has issued a ‘safe to proceed’ for an application for a novel CAR T-cell therapy in CD94-positive lymphomas.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.

Luhua (Michael) Wang, MD, discusses the implications of the FDA approval of brexu-cel for the treatment of adult patients with relapsed/refractory MCL.

Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, discuss their elections as AAAS fellows and offer guidance for early-career investigators.

Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.

Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.

Here is your cheat sheet to all oncology therapeutic options that were cleared or rejected by the FDA in April 2026.

Neil D. Gross, MD, FACS, discusses the importance of year-round vigilance when it comes to skin cancer prevention and education.

Shubham Pant, MD, MBBS, discusses results from the landmark phase 3 RASolute 302 trial for daraxonrasib in previously treated metastatic PDAC.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

Jennifer Wargo, MD, of The University of Texas MD Anderson Cancer Center, has been elected to the 2026 class of Fellows of the American Association for Cancer Research (AACR) Academy.

Luhua (Michael) Wang, MD, discusses the significance of the full FDA approval of brexu-cel in relapsed/refractory mantle cell lymphoma.

Experts highlight ctDNA-guided strategies, ADCs, and targeted therapies shaping CRC research in the first quarter of 2026.

A new study from researchers at The University of Texas MD Anderson Cancer Center shows that a specialized high-dose type of radiation delivery may improve outcomes in cholangiocarcinoma

Shubham Pant, MD, MBBS, discusses recent treatment advancements across gastrointestinal malignancies.

Theresa Guise, MD, and Stephanie S. Watowich, PhD, of The University of Texas MD Anderson Cancer Center, have been elected fellows of the American Association for the Advancement of Science.

Tucatinib and trastuzumab, plus capecitabine, may improve symptoms and extend survival in some breast cancer patients with leptomeningeal metastasis.

Shubham Pant, MD, MBBS, discusses data from the phase 3 BREAKWATER trial supporting upfront targeted therapy in BRAF V600E–mutant mCRC.

Peter WT Pisters, MD, received the Charles M. Balch, MD, Distinguished Service Award at the 2026 Society of Surgical Oncology Annual Meeting 

W. Fraser Symmans, MD, discusses data on the current state of AI-driven digital pathology in HR+ breast cancer.

Eric K. Singhi, MD, discusses where TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan may fit in evolving treatment algorithms in lung cancer.

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center appointed new members to advance the institute’s immunotherapy work.

Jason Aboudi Mouabbi, MD, discusses challenges associated with diagnosing lobular breast cancer and the promising predictive value of FES-PET/CT imaging.